Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico
News Apr 13, 2007
Abbott has announced the official opening of its new biologics manufacturing facility in Puerto Rico to support the long-term supply of its leading biologic agent, HUMIRA® (adalimumab), and other future biologics.
The new facility, Abbott Biotechnology Limited (ABL), received U.S. Food and Drug Administration (FDA) approval in February to commercially produce HUMIRA for the U.S. market.
“This new facility is a key milestone for Abbott as we move to focus our resources and future growth on biologic and potent-drug manufacturing,” said Lawrence Kraus, vice president of manufacturing, global pharmaceutical operations, Abbott.
“The advanced, high-quality infrastructure of ABL can meet the exceptionally challenging and stringent processes of biologic manufacturing. With this state-of-the-art facility, we can supply HUMIRA to the growing number of patients who have come to rely on this breakthrough product,” Kraus added.
"Abbott's new facility expands Puerto Rico's growing presence as the Bio Island. We fully support Abbott's operations in Puerto Rico and will continue to improve our business climate to facilitate future investment among high technology companies like Abbott," said Hon. Anibal Acevedo-Vila, Governor of the Commonwealth of Puerto Rico.
He continued, "Puerto Rico has been a global leader in manufacturing pharmaceutical products for more than 40 years. Our unique combination of incentives, skilled workforce, strong infrastructure and excellent business climate enable us to partner with global industry leaders like Abbott. With the growing presence of Abbott and others, we have the necessary tools to become a global leader in biotechnology as well."
The plant is Abbott’s single-largest capital investment to date, costing approximately $450 million. With this investment, Abbott can achieve large-scale production volumes in biologic manufacturing.
In addition to producing HUMIRA, the 330,000-sq.-ft. facility is designed for large-scale production of future products in Abbott’s pipeline that will require advanced manufacturing technologies.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE